Grit Bio
Grit Bio is a China-based cell therapy company that leads 3 cancer trials in OnCo, testing the tumour-infiltrating lymphocyte therapies GT101 and GT201 and the CAR-T GT719 in cervical cancer, non-Hodgkin lymphoma and advanced solid tumours.
Overview
Grit Bio is a late-stage biopharmaceutical company developing next-generation T-cell therapies for cancer and autoimmune disease, with headquarters in Beijing, a research centre in Shanghai and a GMP manufacturing base in Suzhou. Its pipeline includes GT101, an autologous tumour-infiltrating lymphocyte (TIL) therapy in pivotal development, GT201, a TIL therapy expressing membrane-bound IL-15, CAR-T and CAR-iNKT candidates and neoantigen cancer vaccines. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06241781 (phase 2, Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent...), NCT06948981 (phase 1/2, GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Ma...) and NCT06144671 (phase 1/2, Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +6
- modalities +2
- regions +6
- registry trials +30
Similar pages
not linked directly; found by shared links- TrialClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- TrialA Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
- Trial9-ING-41 in Patients With Advanced Cancers
- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With
Shares Gemcitabine, Cervical cancer.
- CompanyModeX Therapeutics